Lupuzor™ is a potentially breakthrough treatment for lupus, having recently began phase III in Europe and the U.S. under a Special Protocol Assessment (SPA) and Fast Track designation from the U.S. FDA. ImmuPharma holds all worldwide rights of this lead compound.
Lupuzor™ was invented at the Centre National de la Recherche Scientifique, (CNRS) in France, Europe's largest fundamental research insitution with which the ImmuPharma group has a long-standing collaboration. Lupuzor™ has undergone substantial testing, including preclinical development, phase I, phase IIa and phase IIb.
The key highlights and advantages of Lupuzor™ include:
- Unique Mechanism of Action - modulates the immune system to correct its abnormality
- It is a small peptide, not a monoclonal antibody
- Convenient dosing; only a small quantity needed every few weeks
- Good safety profile
- Good eficacy as shown in clinical trials